
    
      This study is to assess the efficacy and safety of Rosuvamibe® (rosuvastatin 10mg/ezetimibe
      10mg) vs. rosuvastatin 20mg treated for 24 weeks in atherosclerotic cardiovascular disease
      risk (≥ 7.5%) patients with type 2 diabetes
    
  